Our feature this week will be a quick look at an insurance company trading at roughly a 60% discount to its peers, even though its growth and risk metrics are equal to or better than those of its peers. Later in the week, I’ll publish a deeper dive into the company and the industry. We opened the September Open Forum by reviewing the Buy on Pullback and Focus Model Portfolios, with much of the discussion centered on stocks where recent results or conference-call commentary strengthened our conviction. The Buy on Pullback portfolio has given back much of its early gain, but we remain focused on whether the underlying company developments are moving in the right direction rather than short-term portfolio performance.

It’s been a little over two months since Phase 1 kicked off, and some of these picks have been on a serious run. The live leaderboard is now available, so you can see how your pick is performing and where you currently stand against the competition.

If there’s one thing I really want to impart on you today in this week’s edition, it’s to start taking these information arbitrage Delta Sheets seriously, especially if you’re a deep-dive research stock picker. Don’t mistake the simplicity of their structure for something simplistic. Take it from someone who’s been doing this for over 30 years. I’m not just saying this because my team created Delta Sheets or because they won’t be free forever. I’m telling you right now: they will help you make money and protect your portfolio from special risk factors that may not have been mentioned in press releases.

We adding Our Feature Stock of the week to our Select Coverage Model Portfolio Universe. If our EPS estimates are on target, the stock should rise 180% to 250% over the next 18 months.

We first wrote up the stock in 2019, right before it went on a 1,367% move. To be clear, COVID was responsible for a good deal of this move. However,  the COVID “bump” eventually ended, so that sales and EPS comps did not look favorable since then… and the stock reversed most of the Multibagger rise.

I think it’s a good idea to do some deeper dives into some of the earnings reports we review within our microcap coverage universe to help you understand what we’re thinking about these companies. To that point, it’s also helpful for our team. So, we will be providing additional coverage on what we talked about during the week regarding RCMT and KLNG. The stocks were up 19.30% and 16.67%, respectively, on the heels of strong earnings reports last week. If you recall, RCMT basically stopped issuing earnings calls and, now, press releases after the fourth quarter of 2025. So it makes this analysis even more important. The cessation of communicating with investors appears to coincide with the company being part of a large data center project, which it still hasn’t formally talked about.

This week, much of our attention was focused on the MS Microcaps Summer Virtual Conference. The three-day event brought together Canadian and U.S. public companies, microcap investors and several discussions around areas we are actively researching. Later in this post, you’ll be able to click on the link to the videos and investor pitches you want to watch. The investor pitch lineup was: Gurkirat Singh, Aurelion Research, Multibagger Mike, Ben Brostoff and Lee Roach. I also threw in my own pitch at the end of the event. Overall, I was extremely impressed with the quality of the pitches, as well as the quality of the stocks that were pitched. I think a portfolio of these stocks will deliver significant alpha.

ICYMI: Reports on two defense stocks we added to our Model Portfolio Universe – one benefiting from rising missile production, and the other experiencing growth catalysts for the first time in a while. The latter’s real estate value on the balance sheet is materially undervalued by a factor of ~4x.

In other news, early research indicates that new products have given this company a “moatish” investment angle. We are starting to get increasingly excited. The company will likely be added to our Model Portfolio Universe.

A US policy shock, a long-running national-security concern about drug supply, finally crystallized into tariffs, is pushing pharmaceutical manufacturing back onto American soil. The result is a domestic capital-expenditure wave estimated at roughly $370–480 billion of announced commitments through 2030. The durable money in this theme does not sit with the drugmakers, for whom reshoring is a cost, but with the “picks and shovels”: the engineering, process-equipment, and consumables suppliers who design, build, and outfit the new plants. Also this week, we sat down again with $FRTU President Yoel Damas to address Geoinvesting subscriber questions about funding capacity, automation, the audit process, and the company’s capital structure. The conversation focused on whether the company can convert growing demand without taking on unfavorable financing.